What is FLGT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.58B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for FLGT?

P/E (TTM) is n/a and 52-week range is $13.46 to $31.04 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s FLGT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for FLGT?

The company profile lists revenue (TTM) near $328M, net income (TTM) near $-8.56B, EPS (TTM) near $-2.83 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Fulgent Genetics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in El Monte, California, US, 28.4M shares outstanding, ISIN US3596641098 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Fulgent Genetics Inc

$FLGT

Health Care · Health Care Providers & Services

IR Run Scenarios

$21.01

-0.24%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in El Monte, California and currently employs 1,315 full-time employees. The company went IPO on 2016-09-28. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

Employees

1,315

Website

www.fulgentgenetics.com/

IPO

2016-09-28

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)